CVXL 0107

Drug Profile

CVXL 0107

Alternative Names: CVXL-0107

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Domain Therapeutics
  • Developer CleveXel Pharma
  • Class Antiparkinsonians
  • Mechanism of Action Glutamate-release-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 31 Dec 2015 CleveXel Pharma completes a proof-of-concept phase IIa trial for Parkinson's disease in France before December 2015
  • 30 Dec 2015 Phase-II clinical trials in Parkinson's disease in France (unspecified route) before December 2015
  • 30 Dec 2015 CleveXel Pharma plans a phase IIa trial for Parkinson's disease (Adjunctive treatment) in France (NCT02641054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top